$26.76
-0.53-1.94%
Last update: 9:30 AM
15 minutes delayed
Comments
Loading...
Beam Therapeutics
BEAMNASDAQ
want to know what
the Bulls & Bears Say?
Beam Therapeutics (NASDAQ:BEAM) Stock, Analyst Ratings, Price Targets, Forecasts
Beam Therapeutics Inc has a consensus price target of $58.93 based on the ratings of 15 analysts. The high is $130 issued by Guggenheim on January 5, 2022. The low is $30 issued by Jefferies on December 8, 2023. The 3 most-recent analyst ratings were released by Barclays, Wedbush, and BMO Capital on May 8, 2024, April 23, 2024, and March 27, 2024, respectively. With an average price target of $49 between Barclays, Wedbush, and BMO Capital, there's an implied 83.11% upside for Beam Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barclays
Wedbush
BMO Capital
RBC Capital
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Beam Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/08/2024 | Buy Now | 23.32% | Barclays | Gena Wang | $42 → $33 | Maintains | Equal-Weight | Get Alert |
| 04/23/2024 | Buy Now | 113% | Wedbush | David Nierengarten | → $57 | Reiterates | Outperform → Outperform | Get Alert |
| 03/27/2024 | Buy Now | 113% | BMO Capital | Kostas Biliouris | → $57 | Maintains | Outperform | Get Alert |
| 02/28/2024 | Buy Now | 56.95% | Barclays | Gena Wang | $26 → $42 | Maintains | Equal-Weight | Get Alert |
| 02/28/2024 | Buy Now | 30.79% | RBC Capital | Luca Issi | $27 → $35 | Maintains | Sector Perform | Get Alert |
| 01/29/2024 | Buy Now | 49.48% | JP Morgan | Eric Joseph | $38 → $40 | Upgrade | Neutral → Overweight | Get Alert |
| 12/15/2023 | Buy Now | 30.79% | B of A Securities | Greg Harrison | → $35 | Downgrade | Buy → Neutral | Get Alert |
| 12/08/2023 | Buy Now | 12.11% | Jefferies | Michael Yee | $75 → $30 | Downgrade | Buy → Hold | Get Alert |
| 10/17/2023 | Buy Now | 19.58% | Cantor Fitzgerald | Rick Bienkowski | $56 → $32 | Maintains | Overweight | Get Alert |
| 09/13/2023 | Buy Now | 109.27% | Cantor Fitzgerald | Rick Bienkowski | → $56 | Reiterates | Overweight → Overweight | Get Alert |
| 08/29/2023 | Buy Now | 109.27% | Cantor Fitzgerald | Rick Bienkowski | → $56 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2023 | Buy Now | 30.79% | Barclays | Gena Wang | $41 → $35 | Maintains | Equal-Weight | Get Alert |
| 08/09/2023 | Buy Now | 75.64% | Credit Suisse | Richard Law | $46 → $47 | Maintains | Neutral | Get Alert |
| 08/09/2023 | Buy Now | 109.27% | Citigroup | Samantha Semenkow | $60 → $56 | Maintains | Buy | Get Alert |
| 05/11/2023 | Buy Now | 56.95% | RBC Capital | Luca Issi | $50 → $42 | Maintains | Sector Perform | Get Alert |
| 05/11/2023 | Buy Now | 53.21% | Barclays | Gena Wang | $45 → $41 | Maintains | Equal-Weight | Get Alert |
| 05/11/2023 | Buy Now | 124.22% | Citigroup | Samantha Semenkow | $62 → $60 | Maintains | Buy | Get Alert |
| 03/21/2023 | Buy Now | 38.27% | Bernstein | William Pickering | → $37 | Initiates | → Market Perform | Get Alert |
| 03/01/2023 | Buy Now | 292.38% | Wells Fargo | Yanan Zhu | $125 → $105 | Maintains | Overweight | Get Alert |
| 02/01/2023 | Buy Now | 131.69% | Cantor Fitzgerald | Rick Bienkowski | → $62 | Initiates | → Overweight | Get Alert |
| 01/23/2023 | Buy Now | 187.74% | SVB Leerink | Mani Foroohar | $81 → $77 | Maintains | Outperform | Get Alert |
| 12/20/2022 | Buy Now | 146.64% | BMO Capital | Kostas Biliouris | $61 → $66 | Upgrade | Market Perform → Outperform | Get Alert |
| 12/13/2022 | Buy Now | 131.69% | Citigroup | Samantha Semenkow | → $62 | Initiates | → Buy | Get Alert |
| 11/08/2022 | Buy Now | 98.06% | Credit Suisse | Richard Law | $65 → $53 | Maintains | Neutral | Get Alert |
| 11/07/2022 | Buy Now | 202.69% | SVB Leerink | Mani Foroohar | $82 → $81 | Maintains | Outperform | Get Alert |
| 08/10/2022 | Buy Now | 124.22% | Barclays | Gena Wang | $38 → $60 | Maintains | Equal-Weight | Get Alert |
| 08/10/2022 | Buy Now | 322.27% | SVB Leerink | Rick Bienkowski | $118 → $113 | Maintains | Outperform | Get Alert |
| 06/17/2022 | Buy Now | 53.21% | BMO Capital | Kostas Biliouris | → $41 | Initiates | → Market Perform | Get Alert |
| 05/09/2022 | Buy Now | 352.17% | SVB Leerink | Rick Bienkowski | $118 → $121 | Maintains | Outperform | Get Alert |
| 04/28/2022 | Buy Now | 131.69% | Credit Suisse | Richard Law | → $62 | Initiates | → Neutral | Get Alert |
| 01/10/2022 | Buy Now | 352.17% | SVB Leerink | Rick Bienkowski | $116 → $121 | Maintains | Outperform | Get Alert |
| 01/05/2022 | Buy Now | 385.8% | Guggenheim | Debjit Chattopadhyay | → $130 | Initiates | → Buy | Get Alert |
| 11/09/2021 | Buy Now | 333.48% | SVB Leerink | Rick Bienkowski | — | Maintains | Outperform | Get Alert |
| 10/19/2021 | Buy Now | 337.22% | SVB Leerink | Rick Bienkowski | — | Initiates | → Outperform | Get Alert |
| 09/10/2021 | Buy Now | 460.54% | B of A Securities | Greg Harrison | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Beam Therapeutics (BEAM) stock?
The latest price target for Beam Therapeutics (NASDAQ:BEAM) was reported by Barclays on May 8, 2024. The analyst firm set a price target for $33.00 expecting BEAM to rise to within 12 months (a possible 23.32% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Beam Therapeutics (BEAM)?
The latest analyst rating for Beam Therapeutics (NASDAQ:BEAM) was provided by Barclays, and Beam Therapeutics maintained their equal-weight rating.
When was the last upgrade for Beam Therapeutics (BEAM)?
The last upgrade for Beam Therapeutics Inc happened on January 29, 2024 when JP Morgan raised their price target to $40. JP Morgan previously had a neutral for Beam Therapeutics Inc.
When was the last downgrade for Beam Therapeutics (BEAM)?
The last downgrade for Beam Therapeutics Inc happened on December 15, 2023 when B of A Securities changed their price target from N/A to $35 for Beam Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Beam Therapeutics (BEAM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beam Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beam Therapeutics was filed on May 8, 2024 so you should expect the next rating to be made available sometime around May 8, 2025.
Is the Analyst Rating Beam Therapeutics (BEAM) correct?
While ratings are subjective and will change, the latest Beam Therapeutics (BEAM) rating was a maintained with a price target of $42.00 to $33.00. The current price Beam Therapeutics (BEAM) is trading at is $26.76, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.